8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K


                             CURRENT REPORT Pursuant
                          to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

     Date of report (Date of earliest event reported):  September 23, 2004


                           Integrated BioPharma, Inc.
             (Exact Name of Registrant as Specified in Its Charter)

                                    Delaware
                 (State or Other Jurisdiction of Incorporation)

          000-28876                                   22-2407475
  (Commission File Number)                  (IRS Employer Identification No.)

                225 Long Avenue
          Hillside, New Jersey 07205
  (Address of Principal Executive Offices)              (Zip Code)

                                 (973) 926-0816
              (Registrant's Telephone Number, Including Area Code)


          (Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written communications pursuant to Rule 425 under the Securities Act
         (17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
         CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
         Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
         Exchange Act (17 CFR 240.13e-4(c))




Item 7.01. Regulation FD Disclosure

         On September 23, 2004,  Integrated  BioPharma,  Inc., a Delaware
corporation (the "Company"),  issued a press release  announcing that its
newly-formed subsidiary (InB/Hauser) completed the purchase of substantially all
of the assets of Hauser Technical Services, Inc (dba Hauser CRO).  The press
release is attached as an exhibit to this Report.


Item 9.01. Financial Statements and Exhibits

(c) Exhibits.

Exhibit No.   Description
99.1          Press Release issued by Integrated BioPharma, Inc. on
              September 23, 2004.

                                       1




                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                  INTEGRATED BIOPHARMA, INC.


Date:  September 23, 2004         By: /s/ Eric Friedman
                                  Eric Friedman
                                  Vice President and Chief Financial Officer

EX-99

                                                                    Exhibit 99.1

NEWS RELEASE for September 23, 2004
Contact: Michael Mason (investors)          Eric Friedman, CFO
         Allen & Caron Inc                  Integrated BioPharma Inc
         212 691 8087                       888 319 6962
         michaelm@allencaron.com            e.friedman@chemintl.com

              INTEGRATED BIOPHARMA COMPLETES HAUSER CRO ACQUISITION

HILLSIDE, NJ (September 23, 2004) ... Integrated BioPharma Inc (AMEX:INB),
announced today that its newly-formed subsidiary (InB/Hauser) completed the
purchase of substantially all of the assets of Hauser Technical Services, Inc
(dba Hauser CRO), including substantially all of its laboratories, development
and manufacturing facilities and equipment; its intellectual property, including
that related to Paclitaxel and other taxanes, goodwill, professional staff and
certain of its ongoing contracts. As part of the transaction InB/Hauser also
acquired Hauser's rights under a prior contract to receive royalties and other
payments from INB's subsidiary, Paxis Pharmaceuticals (Paxis) for Hauser
intellectual property used by Paxis' in the manufacture of Paclitaxel.
Paclitaxel is the first commercial product from Paxis and it was launched
earlier this summer.

INB CEO E. Gerald Kay noted, "Hauser CRO was the original supplier of Paclitaxel
used by Bristol-Myers Squibb for its commercial launch of Taxol more than ten
years ago. Our purchase of this business strengthens our presence in the
pharmaceutical industry and accelerates our ability to become a significant life
sciences company with in-house capability to develop other specialty active
pharmaceutical ingredients (APIs) as well as proprietary technologies for other
INB companies and third-party clients. The acquisition supports our previously
announced strategic plan to diversify through acquisition of related
businesses."

INB CFO Eric Friedman commented, " We saw that Hauser CRO achieved nearly $7.0
million in total revenues in 2002, which produced nearly $1.0 million in
operating income. Its performance then fell apparently due to problems of its
then parent company. Under the INB umbrella we will provide the financial
stability and market presence necessary to support current client activities and
convince new and returning clients to again rely on Hauser CRO for the
laboratory and chemistry expertise they need. We are encouraged by our early
efforts to communicate our plans to all former and potential clients that the
Hauser CRO is on solid footing and planning for the future." Hauser CRO is a
world leader in the extraction, isolation, purification and synthetic
modification of natural products from plant, marine and microbial sources.
Hauser CRO provides research, process development, analytical services,
manufacturing, compliance services and consulting to produce compounds from
natural raw materials for the pharmaceutical, dietary supplement and fine
chemical industries.



Additionally, Hauser CRO is experienced at making milligram to multi-kilogram
quantities of development candidates, natural and synthetic intermediates and
API's for pre-clinical R&D and all phases of clinical trials and commercial use.
Hauser CRO has a proven track record in assisting clients with problem-solving
expertise well beyond the initial drug discovery stage. In addition, Hauser CRO
is the world leader in supplying analytical standards of paclitaxel and related
taxanes.

About Integrated BioPharma Inc (INB)

     INB serves the pharmaceutical, biotech and nutraceutical industries. INB's
biotech subsidiary, NuCycle Therapy, Inc., INB is developing human therapeutics
and preventive compounds using a transient gene expression system and transgenic
plant technology. INB's pharmaceutical subsidiary, Paxis Pharmaceuticals, Inc.,
develops and operates a state-of-the-art GMP facility for the production and
sale of paclitaxel and related drugs.
INB's nutraceutical subsidiary, Manhattan Drug, develops, manufactures and
distributes more than 130 products worldwide. Further information is available
at www.iBioPharma.com.

     Statements included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and the company's
ability to obtain new contracts and accurately estimate net revenues due to
variability in size, scope and duration of projects, and internal issues in the
sponsoring client. Further information on potential risk factors that could
affect the company's financial results can be found in the company's reports
filed with the Securities and Exchange Commission.